---
title: "Varegacestat (AL102) in Desmoid tumors: Care management intervention strategies"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Care management intervention strategies. Topics: Management in designated referral centers with a multidisciplinary tumor board; Imaging schedule during active surveillance; Supportive care, pregnancy, and family planning; Monitoring requirements in the approved gamma secretase inhibitor label; 7 further topics. 11 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Management in designated referral centers with a multidisciplinary tumor board

> “Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

> “Clearly, patients need to be referred to centres with experience in DT to minimize the risk of active surveillance and avoid unnecessarily debilitating or mutilating surgery when possibly needed. Surgery by surgeons without significant experience in the management of DT is strongly discouraged. Similarly, referral to experienced multidisciplinary teams is recommended at the time of initial diagnosis, for optimal advice on safety of an initial observation strategy.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “A multidisciplinary discussion in soft tissue tumor boards is necessary to propose a personalized management; furthermore, a discussion with the patient is also necessary for tailoring this proposal to its objectives given the natural course of the disease.”
> “Second opinion by an expert pathologist as well as clinical management by an expert team is highly recommended”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcomas and the Desmoid Tumor Working Group (DTWG) Global Consensus Paper Guidelines state that diagnosis and treatment be informed and supported by a multidisciplinary team”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.4-2"></a>

### Imaging schedule during active surveillance

> “Active surveillance means that patients need to be continuously monitored with a first MRI (or alternatively CT if MRI is not possible) within 1-2 months, then in 3-6 months intervals.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.4-3"></a>

### Supportive care, pregnancy, and family planning

> “Comprehensive programmes for DT patients should include physical, psychological and social support. A DT is not a contraindication for future pregnancies in favourable evolution and pregnant DT patients should be followed closely by obstetricians and desmoid clinicians.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.”

Source: [Fiore et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40328165/)

<a id="topic-2.2.2.4-4"></a>

### Monitoring requirements in the approved gamma secretase inhibitor label

> “Diarrhea: Severe diarrhea can occur. Monitor and dose modify for Grade 3-4 diarrhea.”
> “Ovarian Toxicity: Female reproductive function and fertility may be impaired. Advise females of reproductive potential of the potential risk prior to treatment and monitor routinely.”
> “Hepatotoxicity: Elevated AST and ALT can occur. Monitor AST and ALT regularly and modify dose as recommended.”
> “Non-Melanoma Skin Cancers: Perform dermatologic examination prior to initiation of OGSIVEO and routinely during treatment.”
> “Electrolyte Abnormalities: Monitor phosphate and potassium regularly and modify dose as recommended.”
> “Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.4-5"></a>

### Diarrhea management with nirogacestat in oncology practices

> “Proactive management strategies, including early patient education, dietary guidance, appropriate pharmacologic intervention, and clear escalation protocols, are essential to ensuring safety and treatment continuity.”
> “We advise patients to stay well hydrated, avoid trigger foods like spicy, greasy, or high-fiber meals, and discontinue stool softeners or laxatives. If symptoms begin, they may take loperamide, but they should reach out if it persists.”
> “We train our nurses to instruct patients on proper loperamide use: two tablets at the onset and one tablet after each episode, with a maximum of eight tablets in a day. If they reach that maximum, they are calling the clinic.”
> “Uncontrolled diarrhea may require treatment interruption or dose reduction.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

<a id="topic-2.2.2.4-6"></a>

### Ovarian toxicity monitoring and fertility counseling

> “Prior to initiating nirogacestat, baseline reproductive hormone levels, including anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol, should be collected. Monitoring continues periodically throughout treatment, and clinicians remain alert to menstrual irregularities and symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.”
> “In addition to symptom monitoring, clinicians discuss fertility preservation with all patients of reproductive potential.”
> “Menstrual changes are tracked during monthly assessments, and symptoms may prompt temporary treatment holds or dose modifications.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

> “The EAG's clinical experts explained that ovarian dysfunction is also a risk with chemotherapy. This is explained to people with childbearing potential and they are offered ovarian preservation. The EAG's clinical experts expected that the same process would be in place for nirogacestat.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

> “Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment; of these, all nine with available menstruation information experienced return of menstruation and eight had FSH WNL at last reported assessment.”

Source: [Loggers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38703010/)

> “Out of nine female patients, two elected to undergo oocyte cryopreservation prior to starting therapy.”

Source: [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)

<a id="topic-2.2.2.4-7"></a>

### Visit and laboratory frequency during nirogacestat treatment

> “Early in therapy, the practices increase visit frequency to assess tolerance and establish a baseline.”
> “I may see them every two to three weeks initially and get lab work accordingly, following what is in the PQI.”
> “upon every clinical visit, we are going to do a CBC and CMP, and a thorough review of systems.”
> “Laboratory assessments typically include liver function tests (LFTs) and phosphorus.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

<a id="topic-2.2.2.4-8"></a>

### Dose modification to maintain gamma secretase inhibitor treatment

> “Nirogacestat is associated with several well-documented adverse events, and dose reductions are common.”
> “if you need a dose reduced or a treatment holiday, that is part of the clinical course and should not be seen as a setback. Staying on therapy at a tolerable dose is the goal.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

> “Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.”

Source: [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)

> “While dose modifications were common, discontinuations were infrequent, making it possible for patients to remain on treatment and achieve continued efficacy benefit.”
> “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months”
> “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months”
> “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.2.2.4-9"></a>

### Onset of adverse events with varegacestat in RINGSIDE Part B

| Adverse event (varegacestat, N=79) | All grades, n (%) | Median time to onset (days) |
| --- | --- | --- |
| Diarrhea | “65 (82.3)” | “14.0” |
| Nausea | “28 (35.4)” | “8.0” |
| Rash | “56 (70.9)” | “24.0” |
| Fatigue | “46 (58.2)” | “27.5” |
| Hypophosphatemia | “27 (34.2)” | “29.0” |
| Ovarian toxicity | “20 (25.3)” | “56.5” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.2.2.4-10"></a>

### Commercial payer prior authorization criteria for nirogacestat

> “Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):”
> “A) Patient is ≥ 18 years of age; AND”
> “B) According to the prescriber, the patient has progressing desmoid tumors; AND”
> “Note: Progressing desmoid tumors are defined as ≥ 20% progression within 12 months.”
> “C) The desmoid tumors are not amenable to surgery or radiotherapy; AND”
> “D) According to the prescriber, the patient requires systemic treatment.”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

> “Approve for 1 year if the patient meets the following (A, B, C, and D):”
> “C) The desmoid tumors are not amenable to surgery or radiotherapy; AND”

Source: [Express Scripts nirogacestat criteria (2023)](https://express-scripts.com/sites/default/files/policies/Oncology%20-%20Ogsiveo%20PA%20Policy.pdf)

> “Ogsiveo may be considered medically necessary if the conditions indicated below are met.”
> “Patient requires systemic treatment”
> “Females of reproductive potential only: patient will be advised to use effective contraception during treatment with Ogsiveo and for 1 week after the last dose”
> “NO disease progression or unacceptable toxicity”
> “300 mg per day”
> “Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Ogsiveo while maintaining optimal therapeutic outcomes.”

Source: [FEP Blue nirogacestat policy 5.21.217 (2026)](https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/October/Pharmacy-Policies/Remove-and-Replace-Update/521217-Ogsiveo-nirogacestat.pdf)

<a id="topic-2.2.2.4-11"></a>

### State Medicaid prior authorization criteria for nirogacestat and new antineoplastics

> “LENGTH OF AUTHORIZATION: Varies; Maximum of one year”
> “Adult patients with progressing desmoid tumors that require systemic treatment.”
> “60 per 30 days (100mg and 150mg)”

Source: [Florida Medicaid oncology prior authorization criteria (2026)](https://ahca.myflorida.com/file/medicaid/Oncology_Criteria_10.01.2026.pdf)

> “To ensure appropriate use for oncology medications based on FDA-approved and compendia-recommended (i.e., National Comprehensive Cancer Network® [NCCN]) indications.”
> “Are there equally or higher recommended alternative agents based on NCCN categories of evidence (Table 1) for the requested indication and place in therapy?”
> “When efficacy is similar, the choice of agent should be determined by safety, and then cost.”
> “New Antineoplastics are immediately subject to the policy and will be added to this table at the next P&T Meeting”

Source: [Oregon Medicaid prior authorization criteria (2025)](https://www.oregon.gov/oha/HSD/OHP/Tools/Oregon%20Medicaid%20PA%20Criteria%20October%201,%202025.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
